Related Experiment Video

Updated: Jun 10, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

391

METTL14-mediated m6A modification upregulated SOCS3 expression alleviates thyroid cancer progression by regulating

Ming Zhou1, Yaqi Zhang2, Qiong Zhang3

  • 1Department of Thyroid Vascular Surgery, Jingzhou Central Hospital, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, 434000, China.

Molecular and Cellular Probes
|October 16, 2024
PubMed

Insights

Methyltransferase-like 14 (METTL14) is reduced in thyroid cancer (TC). Increasing METTL14 inhibits TC progression by regulating the SOCS3/JAK2/STAT3 pathway, offering a potential therapeutic target.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Thyroid cancer (TC) is the most common head and neck malignancy.
  • N6-methyladenosine (m6A) modification is a key epigenetic regulator in cancer.
  • The role of METTL14-mediated m6A in TC is not fully understood.

Purpose of the Study:

  • To investigate the function and mechanism of METTL14 in thyroid cancer progression.
  • To elucidate the regulatory pathway involving METTL14, m6A, SOCS3, and the JAK2/STAT3 signaling pathway in TC.

Main Methods:

  • Analysis of METTL14 expression in TC tissues and cells.
  • In vitro and in vivo experiments to assess the effects of METTL14 upregulation on TC cells.
  • Investigation of the molecular mechanism involving m6A modification, SOCS3 expression, and the JAK2/STAT3 pathway.
  • Utilized JAK2/STAT3 inhibitors (AG490, WP1066) to validate the pathway.

Main Results:

  • METTL14 expression was significantly decreased in TC tissues and cells.
  • METTL14 upregulation suppressed TC cell proliferation, epithelial-mesenchymal transition (EMT), and tumor growth, while inducing apoptosis.
  • METTL14 promoted SOCS3 expression via m6A modification, which in turn inactivated the JAK2/STAT3 pathway.
  • Knockdown of SOCS3 or activation of the JAK2/STAT3 pathway reversed the inhibitory effects of METTL14.

Conclusions:

  • METTL14 acts as a tumor suppressor in thyroid cancer.
  • The METTL14/m6A/SOCS3/JAK2/STAT3 axis is a critical regulator of TC progression.
  • METTL14 represents a potential therapeutic target for thyroid cancer treatment.
Keywords:
Methyltransferase-like 14 (METTL14)N6-methyladenosine (m6A)Suppressor of cytokine signaling 3 (SOCS3)Thyroid cancer

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K
Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

8.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K